Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M
Summary
Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector. The company intends to use the funds to drive the lead program to meaningful clinical data and to build a pipeline of hepatic and extrahepatic targeted therapies. Led by CEO Jeff Walsh, nChroma Bio is a biotechnology company specializes in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. Its integrated product engine tackles significant limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery. nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics, nature’s innate mechanism for gene regulation.